Skip to main content
SpringerLink
Log in
Book cover

Diagnosis and Management of Endocrine Disorders in Interventional Radiology pp 211–230Cite as

Surgical Treatment of Pancreatic Islet Cell Tumors

  • Chapter
  • First Online:

  • 390 Accesses

Abstract

Functional pancreatic neuroendocrine tumors (PNET) are uncommon neoplasms that often present with endocrine hypersecretory syndromes. Patients with underlying genetic disorders, especially multiple endocrine neoplasia type I and von Hippel-Lindau syndrome, are at an increased risk for developing PNETs. Surgical resection is the primary treatment for functional PNETs. However, the decision for surgery depends on multiple factors, including patient functional status and comorbidities, efficacy of medical management of the hypersecretory syndrome, malignant potential of the tumor, size and location of the tumor, presence of metastatic disease, and presence of a genetic tumor syndrome. The extent of surgical resection depends on the size, location, and malignant potential of a tumor and may include enucleation or anatomic resections, such as pancreaticoduodenectomy or distal pancreatectomy. In patients with metastatic disease, tumor debulking plays a key role in aiding the medical management of the hypersecretory syndrome. Interventional ablative and embolization procedures assist in the complex management of unresectable disease. Enhanced recovery after surgery pathways are employed by high-volume centers to help standardize postoperative care.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Vortmeyer AO, Huang S, Lubensky I, Zhuang Z. Non-islet origin of pancreatic islet cell tumors. J Clin Endocrinol Metab. 2004;89(4):1934–8.

    Article  CAS  PubMed  Google Scholar 

  2. Pictet RL, Rall LB, Phelps P, Rutter WJ. The neural crest and the origin of the insulin-producing and other gastrointestinal hormone-producing cells. Science. 1976;191(4223):191–2.

    Article  CAS  PubMed  Google Scholar 

  3. Andrew A, Kramer B, Rawdon BB. The origin of gut and pancreatic neuroendocrine (APUD) cells – the last word? J Pathol. 1998;186(2):117–8.

    Article  CAS  PubMed  Google Scholar 

  4. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Singhi AD, Klimstra DS. Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases. Histopathology. 2018;72(1):168–77.

    Article  PubMed  Google Scholar 

  6. Hodul PJ, Strosberg JR, Kvols LK. Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated? Cancer Control. 2008;15(4):314–21.

    Article  PubMed  Google Scholar 

  7. Hill JS, McPhee JT, McDade TP, Zhou Z, Sullivan ME, Whalen GF, et al. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer. 2009;115(4):741–51.

    Article  PubMed  Google Scholar 

  8. Schurr PG, Strate T, Rese K, Kaifi JT, Reichelt U, Petri S, et al. Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience. Ann Surg. 2007;245(2):273–81.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Lloyd RV, Osamura RY, Klöppel G, Rosai J, World Health O, International Agency for Research on C, et al. WHO classification of tumours of endocrine organs. Lyon: International Agency for Research on Cancer; 2017.

    Google Scholar 

  10. Choe J, Kim KW, Kim HJ, Kim DW, Kim KP, Hong SM, et al. What is new in the 2017 World Health Organization classification and 8th American joint committee on cancer staging system for pancreatic neuroendocrine neoplasms? Korean J Radiol. 2019;20(1):5–17.

    Article  PubMed  Google Scholar 

  11. Basturk O, Yang Z, Tang LH, Hruban RH, Adsay V, McCall CM, et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol. 2015;39(5):683–90.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Basturk O, Tang L, Hruban RH, Adsay V, Yang Z, Krasinskas AM, et al. Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases. Am J Surg Pathol. 2014;38(4):437–47.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Howe JR, Merchant NB, Conrad C, Keutgen XM, Hallet J, Drebin JA, et al. The North American Neuroendocrine Tumor Society consensus paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas. 2020;49(1):1–33.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Nuñez-Valdovinos B, Carmona-Bayonas A, Jimenez-Fonseca P, Capdevila J, Castaño-Pascual Á, Benavent M, et al. Neuroendocrine tumor heterogeneity adds uncertainty to the World Health Organization 2010 classification: real-world data from the Spanish Tumor Registry (R-GETNE). Oncologist. 2018;23(4):422–32.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Da Silva Xavier G. The cells of the Islets of Langerhans. J Clin Med. 2018;7(3):54.

    Article  PubMed Central  CAS  Google Scholar 

  16. Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, et al. Endotext. South Dartmouth: MDText.com, Inc; 2000.

    Google Scholar 

  17. Sadot E, Reidy-Lagunes DL, Tang LH, Do RK, Gonen M, D’Angelica MI, et al. Observation versus resection for small asymptomatic pancreatic neuroendocrine tumors: a matched case-control study. Ann Surg Oncol. 2016;23(4):1361–70.

    Article  PubMed  Google Scholar 

  18. Lee LC, Grant CS, Salomao DR, Fletcher JG, Takahashi N, Fidler JL, et al. Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management. Surgery. 2012;152(6):965–74.

    Article  PubMed  Google Scholar 

  19. Gaujoux S, Partelli S, Maire F, D’Onofrio M, Larroque B, Tamburrino D, et al. Observational study of natural history of small sporadic nonfunctioning pancreatic neuroendocrine tumors. J Clin Endocrinol Metab. 2013;98(12):4784–9.

    Article  CAS  PubMed  Google Scholar 

  20. Toste PA, Kadera BE, Tatishchev SF, Dawson DW, Clerkin BM, Muthusamy R, et al. Nonfunctional pancreatic neuroendocrine tumors <2 cm on preoperative imaging are associated with a low incidence of nodal metastasis and an excellent overall survival. J Gastrointest Surg. 2013;17(12):2105–13.

    Article  PubMed  Google Scholar 

  21. Finkelstein P, Sharma R, Picado O, Gadde R, Stuart H, Ripat C, et al. Pancreatic neuroendocrine tumors (panNETs): analysis of overall survival of nonsurgical management versus surgical resection. J Gastrointest Surg. 2017;21(5):855–66.

    Article  PubMed  Google Scholar 

  22. O’Toole D, Salazar R, Falconi M, Kaltsas G, Couvelard A, de Herder WW, et al. Rare functioning pancreatic endocrine tumors. Neuroendocrinology. 2006;84(3):189–95.

    Article  PubMed  CAS  Google Scholar 

  23. National Comprehensive Cancer Network. Neuroendocrine and adrenal tumors (Version 2.2020). 2020. Available from: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf.

    Google Scholar 

  24. Katabathina VS, Rikhtehgar OY, Dasyam AK, Manickam R, Prasad SR. Genetics of pancreatic neoplasms and role of screening. Magn Reson Imaging Clin N Am. 2018;26(3):375–89.

    Article  PubMed  Google Scholar 

  25. Ehrlich L, Hall C, Meng F, Lairmore T, Alpini G, Glaser S. A review of the scaffold protein Menin and its role in hepatobiliary pathology. Gene Expr. 2017;17(3):251–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Yates CJ, Newey PJ, Thakker RV. Challenges and controversies in management of pancreatic neuroendocrine tumours in patients with MEN1. Lancet Diabetes Endocrinol. 2015;3(11):895–905.

    Article  PubMed  Google Scholar 

  27. Frost M, Lines KE, Thakker RV. Current and emerging therapies for PNETs in patients with or without MEN1. Nat Rev Endocrinol. 2018;14(4):216–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Jensen RT, Norton JA. Treatment of pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: some clarity but continued controversy. Pancreas. 2017;46(5):589–94.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Varshney N, Kebede AA, Owusu-Dapaah H, Lather J, Kaushik M, Bhullar JS. A review of Von Hippel-Lindau syndrome. J Kidney Cancer VHL. 2017;4(3):20–9.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Keutgen XM, Hammel P, Choyke PL, Libutti SK, Jonasch E, Kebebew E. Evaluation and management of pancreatic lesions in patients with von Hippel-Lindau disease. Nat Rev Clin Oncol. 2016;13(9):537–49.

    Article  CAS  PubMed  Google Scholar 

  31. Tirosh A, Sadowski SM, Linehan WM, Libutti SK, Patel D, Nilubol N, et al. Association of VHL genotype with pancreatic neuroendocrine tumor phenotype in patients with von Hippel-Lindau disease. JAMA Oncol. 2018;4(1):124–6.

    Article  PubMed  Google Scholar 

  32. Morgat C, Vélayoudom-Céphise FL, Schwartz P, Guyot M, Gaye D, Vimont D, et al. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1. Eur J Nucl Med Mol Imaging. 2016;43(7):1258–66.

    Article  CAS  PubMed  Google Scholar 

  33. van Asselt SJ, Brouwers AH, van Dullemen HM, van der Jagt EJ, Bongaerts AH, Kema IP, et al. EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1. Gastrointest Endosc. 2015;81(1):159–67.e2.

    Article  PubMed  Google Scholar 

  34. Barbe C, Murat A, Dupas B, Ruszniewski P, Tabarin A, Vullierme MP, et al. Magnetic resonance imaging versus endoscopic ultrasonography for the detection of pancreatic tumours in multiple endocrine neoplasia type 1. Dig Liver Dis. 2012;44(3):228–34.

    Article  PubMed  Google Scholar 

  35. Hashim YM, Trinkaus KM, Linehan DC, Strasberg SS, Fields RC, Cao D, et al. Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs). Ann Surg. 2014;259(2):197–203.

    Article  PubMed  Google Scholar 

  36. Bilimoria KY, Talamonti MS, Tomlinson JS, Stewart AK, Winchester DP, Ko CY, et al. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg. 2008;247(3):490–500.

    Article  PubMed  Google Scholar 

  37. Roland CL, Bian A, Mansour JC, Yopp AC, Balch GC, Sharma R, et al. Survival impact of malignant pancreatic neuroendocrine and islet cell neoplasm phenotypes. J Surg Oncol. 2012;105(6):595–600.

    Article  PubMed  Google Scholar 

  38. Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res. 2008;14(23):7798–803.

    Article  CAS  PubMed  Google Scholar 

  39. Postlewait LM, Ethun CG, Baptiste GG, Le N, McInnis MR, Cardona K, et al. Pancreatic neuroendocrine tumors: preoperative factors that predict lymph node metastases to guide operative strategy. J Surg Oncol. 2016;114(4):440–5.

    Article  PubMed  Google Scholar 

  40. Ballian N, Loeffler AG, Rajamanickam V, Norstedt PA, Weber SM, Cho CS. A simplified prognostic system for resected pancreatic neuroendocrine neoplasms. HPB (Oxford). 2009;11(5):422–8.

    Article  Google Scholar 

  41. Conrad C, Kutlu OC, Dasari A, Chan JA, Vauthey JN, Adams DB, et al. Prognostic value of lymph node status and extent of lymphadenectomy in pancreatic neuroendocrine tumors confined to and extending beyond the pancreas. J Gastrointest Surg. 2016;20(12):1966–74.

    Article  PubMed  Google Scholar 

  42. Tomassetti P, Campana D, Piscitelli L, Casadei R, Santini D, Nori F, et al. Endocrine pancreatic tumors: factors correlated with survival. Ann Oncol. 2005;16(11):1806–10.

    Article  CAS  PubMed  Google Scholar 

  43. DeOliveira ML, Winter JM, Schafer M, Cunningham SC, Cameron JL, Yeo CJ, et al. Assessment of complications after pancreatic surgery: a novel grading system applied to 633 patients undergoing pancreaticoduodenectomy. Ann Surg. 2006;244(6):931–7; discussion 7–9.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Di Sabatino A, Carsetti R, Corazza GR. Post-splenectomy and hyposplenic states. Lancet. 2011;378(9785):86–97.

    Article  PubMed  Google Scholar 

  45. Hernandez MC, Khasawneh M, Contreras-Peraza N, Lohse C, Stephens D, Kim BD, et al. Vaccination and splenectomy in Olmsted County. Surgery. 2019;166(4):556–63.

    Article  PubMed  Google Scholar 

  46. Senthinathan P, Jankar SV, Sabnis SC, Kaje V, Srivatsan Gurumurthy S, Anand Vijai N, et al. Laparoscopic total pancreatectomy for multiple endocrine neoplasia type 1 syndrome-associated multifocal, non-functioning pancreatic neuroendocrine tumor: a case report. Asian J Endosc Surg. 2017;10(4):434–7.

    Article  PubMed  Google Scholar 

  47. Hüttner FJ, Koessler-Ebs J, Hackert T, Ulrich A, Büchler MW, Diener MK. Meta-analysis of surgical outcome after enucleation versus standard resection for pancreatic neoplasms. Br J Surg. 2015;102(9):1026–36.

    Article  PubMed  Google Scholar 

  48. Huang LC, Poultsides GA, Norton JA. Surgical management of neuroendocrine tumors of the gastrointestinal tract. Oncology (Williston Park). 2011;25(9):794–803.

    Google Scholar 

  49. Zogakis TG, Gibril F, Libutti SK, Norton JA, White DE, Jensen RT, et al. Management and outcome of patients with sporadic gastrinoma arising in the duodenum. Ann Surg. 2003;238(1):42–8.

    PubMed  PubMed Central  Google Scholar 

  50. Burghardt L, Meier JJ, Uhl W, Kahle-Stefan M, Schmidt WE, Nauck MA. Importance of localization of insulinomas: a systematic analysis. J Hepatobiliary Pancreat Sci. 2019;26(9):383–92.

    Article  PubMed  Google Scholar 

  51. Spinelli A, Del Fabbro D, Sacchi M, Zerbi A, Torzilli G, Lutman FR, et al. Intraoperative ultrasound with contrast medium in resective pancreatic surgery: a pilot study. World J Surg. 2011;35(11):2521–7.

    Article  PubMed  Google Scholar 

  52. Norton JA, Harris EJ, Chen Y, Visser BC, Poultsides GA, Kunz PC, et al. Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection. Arch Surg. 2011;146(6):724–32.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Thiels CA, Bergquist JR, Laan DV, Croome KP, Smoot RL, Nagorney DM, et al. Outcomes of pancreaticoduodenectomy for pancreatic neuroendocrine tumors: are combined procedures justified? J Gastrointest Surg. 2016;20(5):891–8.

    Article  PubMed  Google Scholar 

  54. Prakash L, Lee JE, Yao J, Bhosale P, Balachandran A, Wang H, et al. Role and operative technique of portal venous tumor thrombectomy in patients with pancreatic neuroendocrine tumors. J Gastrointest Surg. 2015;19(11):2011–8.

    Article  PubMed  Google Scholar 

  55. Prakash L, Bhosale P, Cloyd J, Kim M, Parker N, Yao J, et al. Role of fluorouracil, doxorubicin, and streptozocin therapy in the preoperative treatment of localized pancreatic neuroendocrine tumors. J Gastrointest Surg. 2017;21(1):155–63.

    Article  PubMed  Google Scholar 

  56. Hüttner FJ, Schneider L, Tarantino I, Warschkow R, Schmied BM, Hackert T, et al. Palliative resection of the primary tumor in 442 metastasized neuroendocrine tumors of the pancreas: a population-based, propensity score-matched survival analysis. Langenbeck’s Arch Surg. 2015;400(6):715–23.

    Article  Google Scholar 

  57. Bertani E, Fazio N, Radice D, Zardini C, Spinoglio G, Chiappa A, et al. Assessing the role of primary tumour resection in patients with synchronous unresectable liver metastases from pancreatic neuroendocrine tumour of the body and tail. A propensity score survival evaluation. Eur J Surg Oncol. 2017;43(2):372–9.

    Article  CAS  PubMed  Google Scholar 

  58. Starr JS, Sonbol MB, Hobday TJ, Sharma A, Kendi AT, Halfdanarson TR. Peptide receptor radionuclide therapy for the treatment of pancreatic neuroendocrine tumors: recent insights. Onco Targets Ther. 2020;13:3545–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Bertani E, Fazio N, Radice D, Zardini C, Grana C, Bodei L, et al. Resection of the primary tumor followed by peptide receptor radionuclide therapy as upfront strategy for the treatment of G1-G2 pancreatic neuroendocrine tumors with unresectable liver metastases. Ann Surg Oncol. 2016;23(Suppl 5):981–9.

    Article  PubMed  Google Scholar 

  60. Brighi N, Lamberti G, Maggio I, Manuzzi L, Ricci C, Casadei R, et al. Biliary stone disease in patients receiving somatostatin analogs for neuroendocrine neoplasms. A retrospective observational study. Dig Liver Dis. 2019;51(5):689–94.

    Article  CAS  PubMed  Google Scholar 

  61. Jayakrishnan TT, Groeschl RT, George B, Thomas JP, Clark Gamblin T, Turaga KK. Review of the impact of antineoplastic therapies on the risk for cholelithiasis and acute cholecystitis. Ann Surg Oncol. 2014;21(1):240–7.

    Article  PubMed  Google Scholar 

  62. Mirakhur B, Pavel ME, Pommier RF, Fisher GA, Phan AT, Massien C, et al. Biochemical responses in symptomatic and asymptomatic patients with neuroendocrine tumors: pooled analysis of 2 phase 3 trials. Endocr Pract. 2018;24(11):948–62.

    Article  Google Scholar 

  63. Gerson JN, Witteles RM, Chang DT, Beygui RE, Iagaru AH, Kunz PL. Carcinoid syndrome complicating a pancreatic neuroendocrine tumor: a case report. Pancreas. 2017;46(10):1381–5.

    Article  PubMed  Google Scholar 

  64. Tsoukalas N, Chatzellis E, Rontogianni D, Alexandraki KI, Boutzios G, Angelousi A, et al. Pancreatic carcinoids (serotonin-producing pancreatic neuroendocrine neoplasms): report of 5 cases and review of the literature. Medicine (Baltimore). 2017;96(16):e6201.

    Article  Google Scholar 

  65. Lillemoe HA, Aloia TA. Enhanced recovery after surgery: hepatobiliary. Surg Clin North Am. 2018;98(6):1251–64.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Lavu H, McCall NS, Winter JM, Burkhart RA, Pucci M, Leiby BE, et al. Enhancing patient outcomes while containing costs after complex abdominal operation: a randomized controlled trial of the Whipple accelerated recovery pathway. J Am Coll Surg. 2019;228(4):415–24.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Linnemann RJA, Patijn GA, van Rijssen LB, Besselink MG, Mungroop TH, de Hingh IH, et al. The role of abdominal drainage in pancreatic resection - a multicenter validation study for early drain removal. Pancreatology. 2019;19(6):888–96.

    Article  CAS  PubMed  Google Scholar 

  68. Zaghal A, Tamim H, Habib S, Jaafar R, Mukherji D, Khalife M, et al. Drain or no drain following pancreaticoduodenectomy: the unsolved dilemma. Scand J Surg. 2020;109(3):228–37.

    Article  CAS  PubMed  Google Scholar 

  69. Narayanan S, Martin AN, Turrentine FE, Bauer TW, Adams RB, Zaydfudim VM. Mortality after pancreaticoduodenectomy: assessing early and late causes of patient death. J Surg Res. 2018;231:304–8.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Kagedan DJ, Ahmed M, Devitt KS, Wei AC. Enhanced recovery after pancreatic surgery: a systematic review of the evidence. HPB (Oxford). 2015;17(1):11–6.

    Article  Google Scholar 

  71. Callery MP, Pratt WB, Kent TS, Chaikof EL, Vollmer CM Jr. A prospectively validated clinical risk score accurately predicts pancreatic fistula after pancreatoduodenectomy. J Am Coll Surg. 2013;216(1):1–14.

    Article  PubMed  Google Scholar 

  72. Trudeau MT, Casciani F, Ecker BL, Maggino L, Seykora TF, Puri P, et al. The fistula risk score catalog: toward precision medicine for pancreatic fistula after pancreatoduodenectomy. Ann Surg. 2020; https://doi.org/10.1097/SLA.0000000000004068.

  73. Søreide K, Healey AJ, Mole DJ, Parks RW. Pre-, peri- and post-operative factors for the development of pancreatic fistula after pancreatic surgery. HPB (Oxford). 2019;21(12):1621–31.

    Article  Google Scholar 

  74. Strobel O, Cherrez A, Hinz U, Mayer P, Kaiser J, Fritz S, et al. Risk of pancreatic fistula after enucleation of pancreatic tumours. Br J Surg. 2015;102(10):1258–66.

    Article  CAS  PubMed  Google Scholar 

  75. Chua TC, Yang TX, Gill AJ, Samra JS. Systematic review and meta-analysis of enucleation versus standardized resection for small pancreatic lesions. Ann Surg Oncol. 2016;23(2):592–9.

    Article  PubMed  Google Scholar 

  76. Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, et al. The 2016 update of the international study group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery. 2017;161(3):584–91.

    Article  PubMed  Google Scholar 

  77. Malleo G, Pulvirenti A, Marchegiani G, Butturini G, Salvia R, Bassi C. Diagnosis and management of postoperative pancreatic fistula. Langenbeck’s Arch Surg. 2014;399(7):801–10.

    Article  Google Scholar 

  78. Callery MP, Pratt WB, Vollmer CM Jr. Prevention and management of pancreatic fistula. J Gastrointest Surg. 2009;13(1):163–73.

    Article  PubMed  Google Scholar 

  79. McMillan MT, Fisher WE, Van Buren G 2nd, McElhany A, Bloomston M, Hughes SJ, et al. The value of drains as a fistula mitigation strategy for pancreatoduodenectomy: something for everyone? Results of a randomized prospective multi-institutional study. J Gastrointest Surg. 2015;19(1):21–30; discussion −1.

    Article  PubMed  Google Scholar 

  80. Tseng DS, Molenaar IQ, Besselink MG, van Eijck CH, Borel Rinkes IH, van Santvoort HC. Pancreatic exocrine insufficiency in patients with pancreatic or periampullary cancer: a systematic review. Pancreas. 2016;45(3):325–30.

    Article  CAS  PubMed  Google Scholar 

  81. Rickels MR, Bellin M, Toledo FG, Robertson RP, Andersen DK, Chari ST, et al. Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: recommendations from PancreasFest 2012. Pancreatology. 2013;13(4):336–42.

    Article  CAS  PubMed  Google Scholar 

  82. Wu L, Nahm CB, Jamieson NB, Samra J, Clifton-Bligh R, Mittal A, et al. Risk factors for development of diabetes mellitus (Type 3c) after partial pancreatectomy: a systematic review. Clin Endocrinol. 2020;92(5):396–406.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    Joseph Kearney

  2. Division of Surgical Oncology and Endocrine Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    Jeffrey Johnson & Hong Jin Kim

Authors
  1. Joseph Kearney
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hong Jin Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey Johnson .

Editor information

Editors and Affiliations

  1. Division of Vascular and Interventional RadiologyDepartment of Radiology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA

    Hyeon Yu

  2. Division of Vascular and Interventional RadiologyDepartment of Radiology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA

    Charles T. Burke

  3. Division of Vascular and Interventional RadiologyDepartment of Radiology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA

    Clayton W. Commander

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kearney, J., Johnson, J., Kim, H.J. (2022). Surgical Treatment of Pancreatic Islet Cell Tumors. In: Yu, H., Burke, C.T., Commander, C.W. (eds) Diagnosis and Management of Endocrine Disorders in Interventional Radiology. Springer, Cham. https://doi.org/10.1007/978-3-030-87189-5_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-87189-5_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-87188-8

  • Online ISBN: 978-3-030-87189-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation